All In MedTech

Device Trial Radar · NCT02394379

Post Approval Study to Evaluate the Trulign™ Toric Posterior Chamber IOL

A Prospective, Post Approval Study to Evaluate the Trulign™ Toric Posterior Chamber Intraocular Lens (IOL)

Last checked: Nov 20, 2026Latest source record: Nov 13, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

600

Planned (sponsor's estimate)

Start

Mar 19, 2015

Primary completion

Aug 5, 2019

Study completion Aug 5, 2019

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedNot on our public-company list
Sponsor type
Industry
Collaborators
Bausch Health Americas, Inc.
First posted
Mar 20, 2015

More device trials from this sponsor

Design

Study type
Observational
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the incidence of IOL vaulting (ie, position change) of the Trulign™ Toric IOL following cataract surgery.

Conditions

  • Cataract

Interventions

  • Trulign™ Toric IOLDevice

    Trulign™ Toric Posterior Chamber IOL is a modified plate haptic lens

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of clinically significant IOL vaultingTime frame: Up to 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bausch & Lomb Incorporated

    Rochester, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.